Atlas Trials

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Clinical trial NCT01381692 · COMPLETED

Trial details

NCT number
NCT01381692
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRecurrent Waldenstrom MacroglobulinemiaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone LymphomaRefractory Non-Hodgkin LymphomaRefractory Small Lymphocytic Lymphoma
Start date
2011-07-20
Primary completion
2014-12-08
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.